Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,176
  • Shares Outstanding, K 27,843
  • Annual Sales, $ 1,060 K
  • Annual Income, $ -29,360 K
  • EBIT $ -46 M
  • EBITDA $ -45 M
  • 60-Month Beta 0.82
  • Price/Sales 74.06
  • Price/Cash Flow N/A
  • Price/Book 0.82

Options Overview Details

View History
  • Implied Volatility 135.70% ( -22.80%)
  • Historical Volatility 43.26%
  • IV Percentile 95%
  • IV Rank 75.89%
  • IV High 175.56% on 01/23/24
  • IV Low 10.20% on 08/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 42
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 1.56
  • Today's Open Interest 9,187
  • Open Int (30-Day) 9,181

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.50
  • Number of Estimates 3
  • High Estimate -0.47
  • Low Estimate -0.53
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -127.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.48 +6.85%
on 11/22/24
3.25 -18.46%
on 11/05/24
-0.57 (-17.70%)
since 11/04/24
3-Month
2.48 +6.85%
on 11/22/24
3.44 -22.97%
on 09/09/24
-0.61 (-18.71%)
since 09/04/24
52-Week
2.48 +6.85%
on 11/22/24
5.86 -54.78%
on 01/09/24
-1.50 (-36.14%)
since 12/04/23

Most Recent Stories

More News
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS)...

VTGN : 2.65 (-1.85%)
Vistagen Receives New European Patent for AV-101

Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS)...

VTGN : 2.65 (-1.85%)
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS)...

VTGN : 2.65 (-1.85%)
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS)...

VTGN : 2.65 (-1.85%)
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder

Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS)...

VTGN : 2.65 (-1.85%)
Vistagen to Present at Cowen 43rd Annual Health Care Conference

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS)...

VTGN : 2.65 (-1.85%)
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS)...

VTGN : 2.65 (-1.85%)
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS)...

VTGN : 2.65 (-1.85%)
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS)...

VTGN : 2.65 (-1.85%)
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS)...

VTGN : 2.65 (-1.85%)

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

3rd Resistance Point 2.97
2nd Resistance Point 2.90
1st Resistance Point 2.80
Last Price 2.65
1st Support Level 2.63
2nd Support Level 2.56
3rd Support Level 2.46

See More

52-Week High 5.86
Fibonacci 61.8% 4.57
Fibonacci 50% 4.17
Fibonacci 38.2% 3.77
Last Price 2.65
52-Week Low 2.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar